Poly Medicure
- Market Cap
- ₹16,580 Cr
- P/E
- 52.06
Key Fundamentals
SmallcapHealthcare Equipment & SuppliesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 12.50%
- Debt to Equity
- 0.13
- EPS (TTM)
- ₹31.42
- Book Value
- ₹322.21
- Market Cap
- ₹16,580 Cr
- P/E (TTM)
- 52.06
- P/B
- 5.08
- ROE
- 9.80%
- Dividend Yield
- 0.21%
- EBITDA
- ₹562 Cr
- 52W High
- ₹2,024.00
- 52W Low
- ₹1,182.00
- Day Range
- ₹1,630.60 – ₹1,669.90
- Volume
- 37,535
Peer Comparison
Healthcare › Healthcare Equipment & Supplies › Medical Equipment & Supplies
| 1,495.50 | 102.43 | 17,234 | 12.16 | 0.00% | 13.80% | 18.00% | 1,450 | 142 | |
| 1,635.70 | 52.06 | 16,580 | 5.08 | 0.21% | 9.80% | 12.50% | 2,134 | 316 | |
| 527.60 | 67.64 | 5,363 | 7.68 | 0.00% | 6.59% | 7.34% | 1,316 | 80 | |
| 303.40 | 215.18 | 1,614 | 2.55 | 0.67% | 2.44% | 4.59% | 463 | 7 | |
| 22.33 | 124.06 | 1,560 | 3.35 | 0.21% | 8.91% | 11.40% | 388 | 11 | |
| 187.57 | 31.90 | 1,032 | 3.89 | 0.00% | 14.80% | 15.00% | 294 | 32 | |
| 396.80 | 18.81 | 926 | 1.92 | 0.00% | 26.00% | 22.40% | 350 | 34 | |
| Median 7 companies | 396.80 | 67.64 | 1,614 | 3.89 | 0.00% | 9.80% | 12.50% | 463 | 34 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 37
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 31
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 70
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 73
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 41
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 41
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
2- Company has a low return on equity of 13.3% over last 3 years.
- Debtor days have increased from 83.9 to 103 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 4 | 7 | 8 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 54.07
- Neutral
- MACD (12,26,9)
- 23.12
- Bullish
- SMA (50)
- 1,616.93
- Bullish
- SMA (200)
- 1,548.61
- Bullish
As of
Analyst Rating
3 of 5 analysts rate Buy, 2 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +16.39% |
|---|---|
| 5Y | +19.02% |
| 3Y | +18.92% |
| 1Y | +12.34% |
| TTM | +24.71% |
Net profit
| 10Y | +20.93% |
|---|---|
| 5Y | +18.74% |
| 3Y | +21.49% |
| 1Y | −5.31% |
| TTM | −12.71% |
Operating cash flow
| 10Y | +14.59% |
|---|---|
| 5Y | +15.63% |
| 3Y | +8.80% |
| 1Y | +5.58% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +2.38 pp |
|---|---|
| 5Y | −3.73 pp |
| 3Y | −0.16 pp |
| 1Y | −3.53 pp |
| TTM | −3.85 pp |
Revenue by year
| Mar 2017 | ₹454 Cr |
|---|---|
| Mar 2018 | ₹519 Cr |
| Mar 2019 | ₹610 Cr |
| Mar 2020 | ₹687 Cr |
| Mar 2021 | ₹785 Cr |
| Mar 2022 | ₹922 Cr |
| Mar 2023 | ₹1,115 Cr |
| Mar 2024 | ₹1,375 Cr |
| Mar 2025 | ₹1,669 Cr |
| Mar 2026 | ₹1,875 Cr |
Net profit by year
| Mar 2017 | ₹55.00 Cr |
|---|---|
| Mar 2018 | ₹71.00 Cr |
| Mar 2019 | ₹65.00 Cr |
| Mar 2020 | ₹96.00 Cr |
| Mar 2021 | ₹136 Cr |
| Mar 2022 | ₹147 Cr |
| Mar 2023 | ₹179 Cr |
| Mar 2024 | ₹258 Cr |
| Mar 2025 | ₹339 Cr |
| Mar 2026 | ₹321 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Poly Medicure Ltd trades at ₹1,649.6 with a market cap of ₹16,720.59 Cr and a P/E of 52.5x as of 2026-11-17. The company has delivered strong long-term sales compounding of 16% over 10 years and 19% over 3 and 5 years, but TTM profit has declined 13% and return on equity has trended down from a 10-year average of 15% to 10% in the last year.
- Consistent long-term revenue compounder with 10-year sales CAGR of 16%, 5-year sales CAGR of 19%, and 3-year sales CAGR of 19%, indicating durable demand for its medical devices portfolio.
- TTM revenue growth accelerated to 25%, outpacing its own longer-term compounding rates, suggesting the company may be entering a higher growth phase.
- Very low leverage with a debt-to-equity ratio of just 0.11, providing significant balance sheet headroom for capacity expansion or acquisitions without financial stress.
- 10-year profit CAGR of 20% exceeds the 10-year sales CAGR of 16%, demonstrating long-term operating leverage and margin expansion capability over extended periods.
- Stock has compounded at 24% CAGR over 10 years and 13% over 5 years, reflecting sustained long-term wealth creation for shareholders.
- The stock sits roughly 39.6% above its 52-week low of ₹1,182, suggesting it has recovered meaningfully from its trough and retains investor confidence.
- P/E of 52.5x is elevated, demanding sustained high earnings growth to justify the premium valuation — any earnings miss could trigger significant de-rating.
- TTM profit has declined 13% even as TTM sales grew 25%, pointing to significant margin compression and raising questions about cost control or product mix deterioration.
- Return on equity has deteriorated from a 10-year average of 15% to just 10% in the last year, and the 3-year ROE average of 13% also trails the longer-term trend.
- Debtor days have increased from 83.9 to 103 days, indicating a meaningful deterioration in working capital efficiency and potential collection challenges.
- Price-to-book ratio of 5.12x is elevated and paired with a declining ROE of 10.18%, meaning the market is paying a premium for capital that is generating diminishing returns.
- The 1-year stock CAGR of -13% and 3-year CAGR of just 2% suggest the market has already begun to re-rate the stock downward amid weakening profitability metrics.
- The 5-year profit CAGR of 16% lags the 5-year sales CAGR of 19%, suggesting that over medium-term horizons profit growth has not kept pace with top-line expansion.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: A quiet news cycle for Poly Medicure with no material positive catalysts or emerging risks. Activity is limited to routine governance updates and an upcoming investor conference. The absence of negative developments is reassuring, but investors should watch for any operational or financial updates that may emerge from the Nov 18 meet.
- Investor meet scheduled Nov 18 Nov 13
Poly Medicure officials will participate in an annual investor conference in Mumbai on November 18, 2026, providing institutional visibility.
- Governance policies updated Nov 5
The Board updated policies on material subsidiaries, related party transactions, and insider trading codes on November 5, 2026, reflecting routine compliance upkeep.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 | 444 | 494 | 535 | 525 | 581 |
| Expenses | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 | 382 | 424 | 400 | 443 |
| Operating Profit | 84 | 90 | 96 | 104 | 115 | 114 | 119 | 106 | 115 | 111 | 110 | 125 | 138 |
| OPM % | 25% | 27% | 26% | 27% | 27% | 27% | 27% | 26% | 26% | 23% | 21% | 24% | 24% |
| Other Income | 15 | 17 | 15 | 17 | 27 | 24 | 27 | 43 | 33.94 | 21 | 19 | 33.41 | 30 |
| Interest | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 6 | 6 | 6 | 7.15 |
| Depreciation | 16 | 16 | 16 | 20 | 21 | 21 | 21 | 23 | 25 | 29 | 38 | 36 | 35.05 |
| PBT | 81 | 88 | 92 | 98 | 118 | 113 | 123 | 123 | 122 | 95.93 | 85 | 116 | 125 |
| Tax % | 23% | 26% | 26% | 25% | 26% | 25% | 25% | 24% | 25% | 27% | 24% | 27% | 24% |
| Net Profit | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 | 71 | 65 | 85 | 95.13 |
| EPS (₹) | 6.48 | 6.78 | 7.12 | 7.71 | 8.63 | 8.41 | 9.06 | 9.19 | 9.06 | 7.00 | 6.54 | 8.49 | 9.39 |
| YoY Sales growth | 23 | 19 | 23 | 20 | 25 | 25 | 17 | 5 | 6 | 16 | 21 | 30 | 31 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,670 | 1,875 | 2,134 |
| Expenses | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,213 | 1,429 | 1,650 |
| Operating Profit | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 456 | 446 | 484 |
| OPM % | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% | 24% | 23% |
| Other Income | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 119 | 106 |
| Interest | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 12 | 21 | 26 |
| Depreciation | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 116 | 138 |
| PBT | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 427 | 426 |
| Tax % | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | 25% | 25% | — |
| Net Profit | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 321 | 316 |
| EPS (₹) | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 33.41 | 31.78 | 31.42 |
| Div. Payout % | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% | 10% | 11% | — |
| Sales growth | 21 | 6 | 10 | 14 | 18 | 13 | 14 | 17 | 21 | 23 | 21 | 12 | 25 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 | 51 |
| Reserves | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 3,055 | 3,215 |
| Borrowings | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 | 354 | 412 |
| Other Liabilities | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 | 401 | 478 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,861 | 4,155 |
| Fixed Assets | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,694 | 1,861 |
| CWIP | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 99 | 110 |
| Investments | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,076 | 755 | 746 |
| Other Assets | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 748 | 930 | 1,313 | 1,438 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,861 | 4,155 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 63 | 63 | 56 | 75 | 106 | 131 | 119 | 123 | 191 | 266 | 233 | 246 |
| Investing | −59 | −31 | −56 | −88 | −101 | −109 | −436 | −85 | −179 | −241 | −1,187 | −224 |
| Financing | −6 | −31 | 0 | 16 | −5 | −21 | 317 | −35 | −13 | −20 | 951 | 20 |
| Net Cash Flow | −2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | −1 | 5 | −3 | 43 |
| Free Cash Flow | 13 | 31 | 0 | −7 | 31 | 25 | 24 | −31 | −48 | −9 | −97 | −59 |
| CFO/EBITDA | 101 | 88 | 79 | 80 | 102 | 100 | 75 | 80 | 93 | 94 | 71 | 78 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 | 76 | 103 |
| Inventory Days | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 | 233 | 323 |
| Days Payable | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 | 70 | 91 |
| Cash Conversion Cycle | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 | 239 | 335 |
| Working Capital Days | 25 | 35 | 55 | 71 | 56 | 42 | 74 | 81 | 69 | 54 | 75 | 105 |
| ROCE % | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% | 18% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Poly Medicure insights
65 extracted metrics across FY00–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Mar 2026Transcript PPT Recording
- 24 Jun 2026
- 31 Mar 2025
- 29 Mar 2025
- 29 Feb 2024
- 27 Feb 2023
Frequently Asked Questions about Poly Medicure
What does Poly Medicure Ltd do?
Where is Poly Medicure Ltd (POLYMED) listed?
Which sector does Poly Medicure Ltd belong to?
What is the market capitalisation of Poly Medicure Ltd?
What is the PE ratio of Poly Medicure Ltd?
What is the 52-week high and low of Poly Medicure Ltd?
Does Poly Medicure Ltd pay dividends?
What is the Return on Equity (ROE) of Poly Medicure Ltd?
Company Information
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/POLYMED.md for Poly Medicure Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.